Clear Harbor Asset Management LLC Cuts Position in Amgen Inc. $AMGN

Clear Harbor Asset Management LLC reduced its position in Amgen Inc. (NASDAQ:AMGN) by 24.4% during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 6,582 shares of the medical research company’s stock after selling 2,123 shares during the period. Clear Harbor Asset Management LLC’s holdings in Amgen were worth $2,383,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. Compass Financial Management LLC acquired a new stake in Amgen during the 2nd quarter worth approximately $228,000. Elevation Point Wealth Partners LLC lifted its position in Amgen by 18.9% during the second quarter. Elevation Point Wealth Partners LLC now owns 25,505 shares of the medical research company’s stock valued at $9,236,000 after buying an additional 4,062 shares in the last quarter. Daiichi Life Insurance Co. Ltd. lifted its position in Amgen by 3.9% during the second quarter. Daiichi Life Insurance Co. Ltd. now owns 34,660 shares of the medical research company’s stock valued at $12,551,000 after buying an additional 1,312 shares in the last quarter. Northwestern Mutual Wealth Management Co. grew its stake in Amgen by 1.0% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 58,532 shares of the medical research company’s stock worth $21,196,000 after buying an additional 596 shares during the period. Finally, CFO4Life Group LLC grew its stake in Amgen by 2.6% during the second quarter. CFO4Life Group LLC now owns 1,340 shares of the medical research company’s stock worth $485,000 after buying an additional 34 shares during the period. Hedge funds and other institutional investors own 76.50% of the company’s stock.

Analysts Set New Price Targets

AMGN has been the topic of a number of research reports. UBS Group raised their target price on shares of Amgen from $420.00 to $440.00 and gave the company a “buy” rating in a research note on Wednesday, August 5th. BMO Capital Markets upped their price target on shares of Amgen from $400.00 to $450.00 and gave the stock an “outperform” rating in a research report on Wednesday, August 5th. Robert W. Baird increased their price target on Amgen from $215.00 to $230.00 and gave the company an “underperform” rating in a report on Wednesday, August 5th. Truist Financial raised their price objective on Amgen from $340.00 to $362.00 and gave the company a “hold” rating in a research report on Wednesday, August 5th. Finally, Erste Group Bank restated a “hold” rating on shares of Amgen in a research note on Tuesday, May 5th. One analyst has rated the stock with a Strong Buy rating, thirteen have given a Buy rating, fourteen have assigned a Hold rating and three have assigned a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $380.43.

More Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Solid operating performance and dividend support the valuation. Amgen’s second-quarter results exceeded expectations, with revenue rising year over year and earnings per share topping consensus. Continued growth and the company’s dividend are helping support investor confidence. Amgen stock holds close to record high as Q2 2026 growth and dividend support valuation
• Positive Sentiment: Analysts raised their outlook. Argus increased its price target to $460 from $375 while maintaining a Buy rating, citing the latest quarterly performance and progress across Amgen’s drug portfolio. Separate reports also highlighted favorable forecasts from Mizuho and Cantor Fitzgerald, reinforcing the bullish analyst sentiment. Amgen gets a fresh target
• Positive Sentiment: Tarlatamab development advanced. Amgen’s Phase 3 DeLLphi-315 study is evaluating a subcutaneous injection of tarlatamab against the current intravenous infusion approach in lung cancer. A successful shot formulation could improve convenience and broaden the commercial potential of the drug. Amgen advances tarlatamab shot versus infusion in Phase 3 lung cancer study
• Positive Sentiment: Trading momentum and options activity were unusually strong. Amgen was identified as a momentum stock after a substantial recent share-price rally, while call-option volume surged well above typical levels, suggesting increased bullish positioning.
• Neutral Sentiment: Valuation is becoming a consideration. With the stock near its recent high and analysts raising targets, some commentary questioned whether much of the favorable news is already reflected in the share price, which could limit near-term upside.

Amgen Price Performance

AMGN opened at $439.33 on Friday. Amgen Inc. has a twelve month low of $269.77 and a twelve month high of $443.20. The firm has a market cap of $237.52 billion, a price-to-earnings ratio of 27.30, a PEG ratio of 3.17 and a beta of 0.41. The company has a current ratio of 1.37, a quick ratio of 1.13 and a debt-to-equity ratio of 4.44. The company has a fifty day simple moving average of $379.03 and a 200 day simple moving average of $361.95.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings data on Tuesday, August 4th. The medical research company reported $6.29 EPS for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. The firm had revenue of $10.05 billion for the quarter, compared to analyst estimates of $9.43 billion. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The firm’s revenue was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the business posted $6.02 EPS. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Equities research analysts expect that Amgen Inc. will post 22.92 EPS for the current fiscal year.

Amgen Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a $2.52 dividend. The ex-dividend date is Friday, August 21st. This represents a $10.08 annualized dividend and a dividend yield of 2.3%. Amgen’s payout ratio is 62.65%.

Insider Transactions at Amgen

In other Amgen news, SVP Rachna Khosla sold 2,000 shares of Amgen stock in a transaction that occurred on Tuesday, August 11th. The stock was sold at an average price of $412.57, for a total transaction of $825,140.00. Following the sale, the senior vice president directly owned 6,404 shares in the company, valued at $2,642,098.28. The trade was a 23.80% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, SVP Nancy A. Grygiel sold 2,970 shares of the company’s stock in a transaction that occurred on Thursday, August 6th. The shares were sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the transaction, the senior vice president directly owned 7,340 shares in the company, valued at approximately $2,951,854.40. The trade was a 28.81% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 6,222 shares of company stock valued at $2,540,926 in the last three months. 0.85% of the stock is currently owned by company insiders.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.